Fludarabine
Orphan Drug Cold Chain RequiredFDA Approved
Description
Fludarabine is a purine analog antimetabolite used in conditioning regimens for hematopoietic stem cell transplantation. It is utilized in the treatment of severe combined immunodeficiency and other primary immunodeficiency disorders requiring transplantation. The drug provides immunosuppression and myeloablation necessary for successful engraftment.
Indications & Therapeutic Use
Conditioning regimen for hematopoietic stem cell transplantation, chronic lymphocytic leukemia, severe combined immunodeficiency
Global Availability (6 countries)
| Country | Access Route | Regulatory Pathway | Lead Time | Status |
|---|---|---|---|---|
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — |
Available Through
This drug is available for procurement through the following fulfilment partner.
Fulfilment Partner
Fludarabine
| Generic Name | Fludarabine |
| Brands | 1 brand available |
| Active Ingredient | Fludarabine phosphate |
| Drug Class | Conditioning regimen for hematopoietic stem cell transplantation |
| Manufacturer | Genzyme |
| Dosage Forms | IV infusion, 25mg/mL; Oral tablet, 10mg |
| Medical Code | L01BB05 |
| Orphan Status | Yes — Orphan Drug |
| Cold Chain | Required |
| Lead Time | 10 days |
| Reg. Status | FDA Approved |
| Clinical Trial | NCT00002639 |
| Countries | 6 countries |
Authority Signals
Last Verified3/21/2026
Data ConfidenceHigh (AI + Pharmacist)
Source Citations7 Validated Nodes